Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, announced new employee inducement awards on February 4, 2025. The company granted stock options to one non-executive employee to purchase 35,000 shares at $1.27 per share, and restricted stock units (RSUs) for 20,400 shares to two non-executive employees.
The options will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months. The RSUs will vest over four years, with 25% vesting annually. These grants were approved by the Compensation Committee under the company's Amended and Restated Inducement Equity Plan, complying with Nasdaq Listing Rule 5635(c)(4).
Fate Therapeutics (NASDAQ: FATE), un'azienda biofarmaceutica in fase clinica specializzata in terapie immunologiche derivate da cellule iPSC, ha annunciato nuovi premi per l'induzione dei dipendenti il 4 febbraio 2025. L'azienda ha concesso opzioni azionarie a un dipendente non esecutivo per l'acquisto di 35.000 azioni a 1,27 $ per azione, e unità azionarie ristrette (RSU) per 20.400 azioni a due dipendenti non esecutivi.
Le opzioni saranno maturate in quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura mensilmente nei successivi 36 mesi. Le RSU matureranno su un periodo di quattro anni, con il 25% che matura annualmente. Questi premi sono stati approvati dal Comitato Compensazione ai sensi del Piano di Induzione Azionaria Modificato e Ridefinito dell'azienda, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Fate Therapeutics (NASDAQ: FATE), una empresa biofarmacéutica en fase clínica centrada en terapias inmunológicas derivadas de células iPSC, anunció nuevos premios de inducción para empleados el 4 de febrero de 2025. La empresa otorgó opciones sobre acciones a un empleado no ejecutivo para comprar 35,000 acciones a 1.27 $ por acción, y unidades de acciones restringidas (RSUs) para 20,400 acciones a dos empleados no ejecutivos.
Las opciones se otorgarán durante cuatro años, con el 25% que se liberará después de un año y el 75% restante que se liberará mensualmente durante los siguientes 36 meses. Las RSUs se liberarán durante cuatro años, con el 25% liberándose anualmente. Estos premios fueron aprobados por el Comité de Compensación bajo el Plan de Inducción de Capital Modificado y Reestablecido de la empresa, cumpliendo con la Regla de Listado 5635(c)(4) de Nasdaq.
Fate Therapeutics (NASDAQ: FATE), 임상 단계의 생명공학 회사로 iPSC 유래 세포 면역 치료에 중점을 두고 있는 회사가 2025년 2월 4일 새로운 직원 유인 보상을 발표했습니다. 이 회사는 한 비임원 직원에게 주당 1.27$에 35,000주를 구매할 수 있는 주식 옵션을 부여했으며, 두 명의 비임원 직원에게는 20,400주의 제한 주식 단위(RSU)를 부여했습니다.
옵션은 4년 동안 분할 지급되며, 1년 후 25%가 지급되고, 나머지 75%는 다음 36개월 동안 매월 지급됩니다. RSU는 4년 동안 분할 지급되며, 매년 25%가 지급됩니다. 이러한 보상은 회사의 수정 및 재정립된 유인 자본 계획에 따라 보상 위원회에서 승인되었으며, Nasdaq 상장 규칙 5635(c)(4)에 부합합니다.
Fate Therapeutics (NASDAQ: FATE), une entreprise bio-pharmaceutique en phase clinique axée sur les thérapies immunologiques dérivées de cellules iPSC, a annoncé de nouvelles récompenses d'induction pour les employés le 4 février 2025. L'entreprise a accordé des options d'achat d'actions à un employé non cadre pour l'achat de 35 000 actions au prix de 1,27 $ par action, et des unités d'actions restreintes (RSU) pour 20 400 actions à deux employés non cadres.
Les options matureront sur quatre ans, avec 25 % qui mûrissent après un an et les 75 % restants qui mûrissent chaque mois pendant les 36 mois suivants. Les RSU mûriront également sur quatre ans, avec 25 % qui mûrissent annuellement. Ces attributions ont été approuvées par le Comité de Rémunération dans le cadre du Plan de Capital d'Induction Modifié et Révisé de l'entreprise, en conformité avec la Règle de Cotation Nasdaq 5635(c)(4).
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf iPSC-abgeleitete zelluläre Immuntherapien spezialisiert hat, gab am 4. Februar 2025 neue Anreizauszeichnungen für Mitarbeiter bekannt. Das Unternehmen gewährte einem nicht-executive Mitarbeiter Aktienoptionen zum Kauf von 35.000 Aktien zu je 1,27 $, sowie beschränkte Aktieneinheiten (RSUs) für 20.400 Aktien an zwei nicht-executive Mitarbeiter.
Die Optionen werden über vier Jahre vesten, wobei 25% nach einem Jahr und die verbleibenden 75% monatlich über die folgenden 36 Monate vesten. Die RSUs werden ebenfalls über vier Jahre vesten, wobei 25% jährlich vesten. Diese Auszeichnungen wurden vom Vergütungsausschuss im Rahmen des überarbeiteten Anreizaktienplans des Unternehmens genehmigt, und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on February 3, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 35,000 shares of the Company’s common stock at an exercise price per share of
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
What is the exercise price of FATE's new stock options granted on February 3, 2025?
How many shares are covered by FATE's February 2025 employee inducement awards?
What is the vesting schedule for FATE's February 2025 stock option grants?
How do the RSUs vest in FATE's February 2025 inducement awards?
